Approvals

The Ministry of Health, Labour and Welfare Japan has approved treatment for Eli Lilly’s Kisunla, indicated for adult patients with early symptomatic Alzheimer’s disease (AD). This also includes patients with mild dementia stage AD, and mild cognitive impairment.

Kisunla can help the body remove the excessive build-up of amyloid plaques and slow the decline that may diminish people’s ability to remember new information, according to the press release. This will enable patients to recall important dates and appointments, make meals, use household appliances, plan and organise, and manage their own finances.

Ilya Yuffa, executive vice president of Eli Lilly and Company, and president of Lilly International, commented: “Kisunla demonstrated very meaningful results for people with early symptomatic AD by significantly slowing cognitive and functional decline in our TRAILBLAZERALZ 2 study, which included participants from Japan.

People around the world want and deserve access to treatment options for this devastating disease. Today’s news is another critical step in ensuring patients with AD can receive treatment with these first-class amyloid therapies, which could give them more time to do what matters most to them.”